Are Admission Plasma Fibrinogen Levels Useful in the Characterization of Risk Groups after Myocardial Infarction Treated with Fibrinolysis?

Summary

The aim of our study was to prove or disprove the independent prognostic importance of fibrinogen after myocardial infarction. Plasma fibrinogen levels were determined on admission in 135 patients with an acute myocardial infarction and symptoms up to 4 h (mean: 1.8 h) immediately before starting fibrinolytic treatment with 1.5 mio U. streptokinase i.v. All patients were free from other diseases which are known to cause elevated fibrinogen levels. Coronary angiography was carried out in 87%. During a mean follow-up period of 26.2 months 31 coronary events could be observed in 26 patients: 18 reinfarctions, 6 cases of sudden death, and 7 coronary artery bypass graft surgeries because of new symptoms. While plasma fibrinogen levels were higher in smokers than in non-smokers (3.30 vs 2.94 g/l p = 0.011) and correlated with the number of involved coronary arteries (p = 0.08), values were similar in patients with and without coronary events during follow-up (3.07 vs 3.16 g/l, p = 0.70). This applied as well to univariate analysis as to multivariate Cox's regression model. We conclude that plasma fibrinogen levels determined very early in patients with acute myocardial infarction do correlate with other important prognostic variables, but have no independent prognostic importance.

• References

• 1 Schmechel H, Beiküfner P, Panzram G. Lôngsschnittuntersuchungen zur prognostischen Bedeutung des Plasmafibrinogens beim Diabetes mellitus. Z Ges Inn Med 1984; 39: 453-7
• 2 Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: Insights from the Framingham Study. Am Heart J 1987; 113: 1006-10
• 3 Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Thompson SG. Haemostatic function and cardiovascular death:. 1050-4
• 4 Wilhelmsen L, Svôrdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5
• 5 Balleisen L, Schulte H, Assmann G, Epping PH, Van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; II: 461
• 6 Nicolaides AN, Horbourne T, Bowers R, Kidner PH, Besterman EM. Blood viscosity, red-cell flexibility, haematocrit, and plasma-fibrinogen in patients with angina. Lancet 1977; I I 943-5
• 7 Kleophas W, Leschke M, Tschöpe D, Martin J, Schauseil S, Schottenfeld Y, Strauer BE, Gries FA. Akute Wirkungen der extrakorporalen LDL-Cholesterin- und Fibrinogen-Elimination auf Blutrheologie und Mikrozirkulation. Dtsch Med Wschr 1990; 115: 3-7
• 8 Kostis JB, Kominos V, Cosgrove NM, Moreyra AE. Fibrinogen and angiographically demonstrable coronary artery disease. Circulation 1988; 78 (Suppl II) 11
• 9 Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, Hiroki T, Arakawa K. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-13
• 10 Copley A. Fibrin(ogen), platelets and a new theory of atherogenesis. Thromb Res 1979; 14: 249-63
• 11 Eastham RD, Cantab MD, Morgan EH. Plasma-fibrinogen levels in coronary-artery disease. Lancet 1963; II: 1196-7
• 12 Dodds AJ, Boyd MJ, Allen J, Bennett ED, Flute PT, Dormandy JA. Changes in red cell deformability and other haemorrheological variables after myocardial infarction. Br Heart J 1980; 44: 508-11
• 13 Dube B, Somani PN, Tripathi GK, Dube RK, Bhattacharya SK. Plasma fibrinogen, fibrinolytic activity and serum fibrinogen/fibrin degradation products in ischaemic heart disease. JAPI 1985; 33: 784-7
• 14 Saxena KK, Gupta B, Gopal R, Srivastava SSL, Singh RC, Kulshrestha VK, Prasad DN. Plasma fibrinogen and serum enzymes: Relative significance as prognostic indicator in acute myocardial infarction. JAPI 1986; 34: 641-2
• 15 Haines AP, Howarth D, North WRS, Goldenberg E, Stirling Y, Meade TW, Raftery EB, Millar Craig MW. Haemostatic variables and the outcome of myocardial infarction. Thromb Haemostas 1983; 50: 800-3
• 16 Kostis JB, Baughman J, Kuo PT. Association of recurrent myocardial infarction with hemostatic factors: a prospective study. Chest 1982; 81: 571-5
• 17 Deryagina GP. The prognostic significance of the status of the blood coagulation system for the development of myocardial infarction and sudden death in coronary heart disease patients. Kardiologiia 1984; 24: 69-73
• 18 Hamsten A, Walldius G, Szamosi A, Blombôck M, DeFaire U, Dahlén G, Landou C, Wiman B. Plasminogen activator inhibitor in plasma:. 3-9
• 19 Kostis JB. Fibrinolysis and recurrence of myocardial infarction. Lancet 1987; II: 462
• 20 The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 8th ed. Little, Brown and Company, Boston, MA: 1979. pp 91-119
• 21 The principal investigators of CASS and their associates The National Heart, Lung, and Blood Institute Coronary Artery Surgery Study (CASS). Circulation 1981; 63 (Suppl I) 1-81
• 22 Roberts WC. Sudden cardiac death: Definitions and causes. Am J Cardiol 1986; 57: 1410-3
• 23 Clauss VA. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-46
• 24 Dixon WJ. BMDP Statistical Software. University of California Press, Berkeley, CA: 1983
• 25 Chakrabarti R, Hocking ED, Fearnley GR. Reaction pattern to three Stresses – electroplexy, surgery and myocardial infarction – of fibrinolysis and plasma fibrinogen. J Clin Pathol 1969; 22: 659-62
• 26 Schaer DH, Ross AM, Wassermann AG. Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy. Circulation 1987; 76 (Suppl II) 57-62
• 27 Dantzig van JM, Becker AE. Sudden cardiac death and acute pathology of coronary arteries. Eur Heart J 1986; 7: 987-91
• 28 Davies MJ, Thomas AT. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137-40
• 29 De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
• 30 Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. JACC 1988; 12: 56-62
• 31 Epstein SE, Quyyumi AA, Bonow RO. Sudden cardiac death without warning. Possible mechanisms and implications for screening asymptomatic populations. NEJM 1989; 321: 320-3
• 32 Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?. Circulation 1988; 78: 1157-66
• 33 Simoons ML, Brand M, DeZwaan C, Verheugt FWA, Remme WJ, Serruys PW, Bôr F, Res J, Krauss XH, Vermeer F. Improved survival after early thrombolysis in acute myocardial infarction. Lancet 1985; I I 578-82
• 34 Kimbiris D, Segal BL. Coronary disease progression in patients with and without saphenous vein bypass surgery. Am Heart J 1981; 102: 811-8
• 35 Deutsch E. Blutgerinnung und Fibrinolyse. In: Laboratoriumsdiagnostik, Normalbereich der Ergebnisse und Interpretation abnormer Befunde.. Deutsch E, Geyer G. (eds) Karger, Basel: 1975. pp 289-355
• 36 Gruppo Italiano per lo Studio della Streptochinasi Nell'Infarto Miocardico (GISSI) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-401
• 37 Geltman EM. Conservative management after thrombolysis: The strategy of choice. Editorial Comment. JACC 1990; 16: 1535-7
• 38 De Feyter PJ, van Eenige MJ, Dighton DH, Visser FC, DeJong J, Roos JP. Prognostic value of exercise testing, coronary angiography and left ventriculography 6-8 weeks after myocardial infarction. Circulation 1982; 66: 527-36